Conference Coverage

Raltegravir not associated with IRIS in African trial

 

Key clinical point: Amid concern to the contrary, integrase inhibitors might not trigger IRIS in the severely immunocompromised.

Major finding: IRIS events – 225 fatal and 113 nonfatal – occurred in 9.9% of patients in the raltegravir arm and 9.5% of patients on standard treatment (P = .79).

Study details: Randomized trial with 1,805 subjects

Disclosures: The work was supported by the U.K. Department for International Development, the Wellcome Trust, and others. The lead investigator had no disclosures.

Source: Gibb D et al. CROI, Abstract 23.


 

REPORTING FROM CROI

– A randomized trial in sub-Saharan Africa found no evidence that first-line raltegravir (Isentress)triggers immune reconstitution syndrome in HIV patients.

It’s an important finding because raltegravir and other integrase inhibitors are replacing nonnucleoside reverse-transcriptase inhibitors (NNRTIs) as first-line treatments for HIV. There have been a few reports from observational studies that among severely immunocompromised, the rapid drop in viral load (VL) with the drugs might trigger immune reconstitution syndrome (IRIS), an exaggerated, dysfunctional, and sometimes fatal response to pathogens as the immune system begins to recover.

Dr. Diana Gibb, an epidemiology professor and researcher at the University College London Alex Otto/Frontline Medical News

Dr. Diana Gibb

That’s not what happened in Uganda, Zimbabwe, Malawi, and Kenya, however.

The 1,805 subjects in those four countries – a few children, but mostly adults – started the trial with median baseline CD4 counts of 37 cells/mcL and VLs of 249,770 copies/mL; 903 were randomized to standard treatment with two nucleoside reverse transcriptase inhibitors plus one NNRTI (Efavirenz), while 902 were randomized to the same regimen but with raltegravir during the first 12 weeks.

As expected, VLs came down very fast in the raltegravir group to a mean of only 80 copies/mL at 4 weeks, vs. a mean of 480 copies/mL in the standard treatment arm.

After a median of about a month, 225 fatal and 113 nonfatal IRIS events (adjudicated by a review committee blinded to randomization) occurred in 9.9% of patients in the raltegravir arm and 9.5% of patients on standard treatment, a nonsignificant difference (P = .79). IRIS was fatal in 4% of raltegravir patients and 3.4% of standard-care patients, also a nonsignificant difference (P = .54).

Next Article:

   Comments ()